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Abstract  18 
Human cytomegalovirus (HCMV) primary infection and periodic re-activation of latent virus is 19 
generally well controlled by T-cell responses in healthy people.  In older donors, overt HCMV 20 
disease is not generally seen despite the association of HCMV infection with increased risk of 21 
mortality.  However, increases in HCMV-DNA in urine of older people suggest that, although the 22 
immune response retains functionality, immunomodulation of the immune response due to lifelong 23 
viral carriage may alter its efficacy.  Viral transcription is limited during latency to a handful of viral 24 
genes and there is both an IFNγ and cellular IL-10 CD4+ T-cell response to HCMV latency-25 
associated proteins.  Production of cIL-10 by HCMV-specific CD4+ T-cells is a candidate for ageing 26 
related immunomodulation.  To address whether long-term carriage of HCMV changes the balance 27 
of cIL-10 and IFNγ secreting T-cell populations, we recruited a large donor cohort aged 23–78 years 28 
and correlated T-cell responses to 11 HCMV proteins with age, HCMV-IgG levels, latent HCMV-29 
load in CD14+ monocytes and T-cell numbers in the blood.   IFNγ responses by CD4+ and CD8+ T-30 
cells to all HCMV proteins were detected, with no age-related increase in this cohort.  IL-10 31 
secreting CD4+ T cell responses were predominantly to latency-associated proteins but did not 32 
increase with age.  Quantification of HCMV genomes in CD14+ monocytes, a known site of latent 33 
HCMV carriage, did not reveal any increase in viral genome copies in older donors.  Importantly, 34 
there was a significant positive correlation between the latent viral genome copy number and the 35 
breadth and magnitude of the IFNγ T-cell response to HCMV proteins.  This study suggests in 36 
healthy aged donors that HCMV specific changes in the T cell compartment were not affected by age 37 
and were effective, as viremia was a very rare event.  Evidence from studies of unwell aged has 38 
shown HCMV to be an important co-morbidity factor,  surveillance of latent HCMV load and low-39 
level viremia in blood and body fluids, alongside typical immunological measures and assessment of 40 
the anti-viral capacity of the HCMV-specific immune cell function would be informative in 41 
determining if anti-viral treatment of HCMV replication in the old maybe beneficial.   42 
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Introduction 43 
A consequence of ageing in the human population is a decline in immune function, often described as 44 
immune senescence, which includes a loss of adaptive immune cells and an increase in inflammatory 45 
cytokines resulting in dysregulation of the immune response (McElhaney and Effros, 2009).  There is 46 
now evidence from a number of studies that, after the age of 65, the age associated loss of immune 47 
function results in individuals becoming more susceptible to infectious diseases as well as increased 48 
morbidity and mortality from autoimmune disorders (Denkinger et al., 2015; Kline and Bowdish, 49 
2016).  Infection with human cytomegalovirus (HCMV) is characterized by its life-long persistence 50 
in the infected individual due, in part, to its ability to establish a latent infection in bone marrow stem 51 
cells and myeloid cells (Sinclair and Sissons, 2006).  Despite a robust immune response to the 52 
primary infection, the large number of immune evasion molecules encoded by HCMV allows it to 53 
establish its latent life cycle (Wills et al., 2015).  Primary HCMV infection and reactivation from 54 
latency is generally well controlled in healthy individuals; however, when the immune system is 55 
compromised, or under developed, it can become a significant problem (Crough and Khanna, 2009; 56 
Jackson et al., 2011).  A potential impact of lifelong persistence of HCMV is its effect on the host 57 
immune response with ageing. A number of longitudinal and population cohort studies have 58 
suggested that HCMV sero-positivity was linked to age-related (i) increase in susceptibility to 59 
infections, (ii) poor response to vaccinations and (iii) increased risk of all-cause mortality compared 60 
to age matched HCMV sero-negative individuals – which has been termed the Immune Risk 61 
Phenotype (IRP) (Olsson et al., 2001; Wikby et al., 2002; Trzonkowski et al., 2003; Ouyang et al., 62 
2004; Hadrup et al., 2006; Strindhall et al., 2013).  Analysis of a number of large population cohorts 63 
recruited for cancer, dementia and nutritional studies in the UK and USA have also shown a 64 
significant association between HCMV sero-positivity and mortality from cardiovascular related 65 
disease (Simanek et al., 2011; Gkrania-Klotsas et al., 2012; Olson et al., 2013; Savva et al., 2013; 66 
Spyridopoulos et al., 2016).  However, other studies have shown no such age-related correlation 67 
between HCMV sero-positivity and declines in immune responses to either novel infections (Lelic et 68 
al., 2012; Schulz et al., 2015) or responses to vaccination (Furman et al., 2015).  Similarly, a study 69 
measuring frailty in older people saw a positive association with inflammatory cytokines but not 70 
HCMV infection (Collerton et al., 2012) perhaps consistent with studies that have shown that rises in 71 
inflammatory cytokines in the serum of older donors is not primarily driven by HCMV (Bartlett et 72 
al., 2012). 73 
It has been observed that infection with HCMV changes the composition of the CD4+ and CD8+ 74 
memory T cell repertoires; this includes an expansion of the T cell population which have lost 75 
expression of the co-stimulatory molecules CD27 and CD28 but also show re-expression of CD45RA 76 
and co-expression of  the carbohydrate HNK-1 (CD57) (reviewed in (Weltevrede et al., 2016)). Such 77 
T cells are considered to be a highly differentiated phenotype (Harari et al., 2004), and potentially 78 
dysfunctional as they often lose the ability to secrete cytokines and have limited proliferative 79 
capacity (Ouyang et al., 2004; Henson et al., 2009).  It has been suggested that expanded populations 80 
of highly differentiated T cells in HCMV sero-positive older donors may be detrimental to the 81 
infected individual (Vescovini et al., 2010; Derhovanessian et al., 2014; Broadley et al., 2017).  82 
However, such increases in these highly differentiated T cells is also observed in young HCMV 83 
I r v
w
HCMV T-cell Responses in Ageing 
 
4 
positive individuals (Miles et al., 2007) and it is, also, now clear that these highly differentiated T 84 
cells are still functional and, with the correct co-stimulation, can proliferate (Waller et al., 2007; 85 
Riddell et al., 2015). Similarly, HCMV specific T cells have been shown to produce multiple anti-86 
viral cytokines and have efficient cytotoxic capacity despite a highly differentiated phenotype 87 
(Casazza et al., 2006; Lachmann et al., 2012; Riou et al., 2012).  Furthermore, older HCMV sero-88 
positive individuals do not appear to suffer from overt HCMV disease from reactivating virus or 89 
HCMV re-infection which suggests that the immune response of older people retains the ability to 90 
control virus replication (Stowe et al., 2007).  Despite older HCMV sero-positive donors having 91 
functional HCMV specific immune responses, there does appear to be age-related increases in levels 92 
of viral DNA detectable in urine (Stowe et al., 2007) and blood (Furui et al., 2013). This suggests 93 
that the immune response in older people may be altered, possibly due to lifelong carriage of the 94 
virus, and that immunomodulation of the HCMV specific immune response, as either a direct 95 
consequence of the viral infection or bystander effects, results in reduced clearance of reactivating 96 
virus in older people (Wills et al., 2015).   97 
Latent carriage of HCMV in CD34+ progenitor cells and their myeloid derivatives is characterized 98 
by repression of viral immediate Early (IE) gene transcription with a restricted gene expression 99 
profile which cannot support production of infectious virus.   A number of viral genes have been 100 
identified as being transcribed during HCMV latent infection, including UL138 (Goodrum et al., 101 
2007), LUNA (latent undefined nuclear antigen; UL81-82as) (Bego et al., 2005; Reeves and Sinclair, 102 
2010), US28 (Beisser et al., 2001), UL111A (vIL-10) (Jenkins et al., 2004) and UL144 (Poole et al., 103 
2013).  Analysis of the secreted cellular proteins (cell secretome) of experimentally latently infected 104 
CD34+ and CD14+ cells have identified the induced expression of chemokines which can recruit T 105 
cells as well as the cellular cytokines IL-10 and TGF-β, both of which can modulate the activity of T 106 
cells which have migrated to the environment surrounding the latent infection (Mason et al., 2012).  107 
HCMV specific CD4+ T cells have been identified that either secrete cIL-10 or have a regulatory cell 108 
phenotype (Tovar-Salazar et al., 2010; Schwele et al., 2012; Terrazzini et al., 2014; Derhovanessian 109 
et al., 2015; Clement et al., 2016) and, in the mouse, it has been shown that CD4+ T regulatory cells 110 
(Tregs) and IL-10 secretion can reduce viral clearance and increase persistence in murine 111 
cytomegalovirus (MCMV) (Jost et al., 2014; Clement et al., 2016).  Additionally, there is evidence 112 
that the frequency of HCMV specific inducible Tregs is increased in older individuals (Terrazzini et 113 
al., 2014), alongside an overall increase in frequency of T regulatory cells in old age (Gregg et al., 114 
2005; Chidrawar et al., 2009).  Previously, we have identified CD4+ T cells specific for peptides to 115 
two of the latency-associated proteins, UL138 and LUNA which secrete cIL-10 and also possess Th1 116 
anti-viral effector functions (Mason et al., 2013). We have also shown that the UL138 specific CD4+ 117 
T cells recognize experimentally latently infected CD14+ monocytes, secrete cIL-10 and suppress T 118 
cell function.    119 
 120 
With these observations in mind, we hypothesized that the long term carriage of HCMV could create 121 
an immunomodulatory environment to help prevent clearance of the virus by skewing the CD4+ T 122 
cell compartment towards a suppressive or regulatory cIL-10 producing phenotype.  We also wanted 123 
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5 
to assess whether the same environment had an impact on the frequency of HCMV specific CD8+ T 124 
cells within a large old aged donor cohort, who have carried HCMV for longer compared to younger 125 
sero-positive donors.  Additionally, within the study, we wanted to measure the levels of latent viral 126 
genome carriage and determine if infectious virus was detectable and relate this to changes in the T 127 
cell response.  To address these questions, we conducted a study on a large healthy donor cohort 128 
which encompassed a broad age range (23 – 78 years) of both HCMV sero-positive and negative 129 
donors.  We performed absolute cell counts, measured HCMV specific antibody levels, assayed viral 130 
genome copy number in total peripheral blood and in CD14+ cells as well as measuring the CD8+ 131 
specific production of IFNγ and CD4+ specific production of IFNγ and IL-10 in response to 132 
stimulation by overlapping peptide pools to eleven HCMV proteins (5 latency associated and 6 lytic 133 
only expressed proteins).   The study group exhibited typical age-related decline in both absolute 134 
CD4+ and CD8+ naïve T cell numbers and HCMV sero-positive donors had increased absolute 135 
numbers of T cells with a differentiated phenotype compared to sero-negative donors.  We did not 136 
see an inversion of the CD4:CD8 ratio within this donor cohort, a characteristic associated with the 137 
IRP, although CD4:CD8 ratio was decreased in HCMV sero-positive donors compared to sero-138 
negative.   In contrast to studies in other donor cohorts, we did not see an age related expansion of the 139 
HCMV IgG response or an influence of donor age on either the breadth or magnitude of the T cell 140 
responses (Parry et al., 2016; Weltevrede et al., 2016). We detected both CD4+ and CD8+ specific 141 
IFNγ responses to all 11 HCMV proteins analyzed and also detected more limited CD4+ specific IL-142 
10 responses to the same proteins, we also confirmed our previous observations that CD4+ specific 143 
IL-10 responses are more common towards latency associated proteins.   We were able to detect 144 
latent HCMV genomes in isolated peripheral blood CD14+ monocytes in 45% of donors but, in 145 
contrast to previous reports (Parry et al., 2016), we did not observe an increase in HCMV copy 146 
number in donors aged over 70 years old.  Importantly, we did see a significant association between 147 
the levels of HCMV detected in CD14+ monocytes and both the breadth and magnitude of the CD8+ 148 
T cell responses to HCMV proteins, irrespective of donor age.   Overall it is our opinion that larger 149 
latent HCMV reservoirs will lead to increased HCMV reactivation and dissemination events, which 150 
in normal healthy individuals will stimulate secondary HCMV specific T cell responses, thus driving 151 
increases in T cell frequency and differentiation status.     152 
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Materials and methods 153 
 154 
Ethics and Donor Cohort information 155 
The study donor cohort was recruited by the National Institute of Health Research (NIHR) 156 
Cambridge BioResource, using their Biobank of volunteers, who predominantly are local to 157 
Cambridge or live in the East Anglian Region of the United Kingdom.  Ethical approval was 158 
obtained from University of Cambridge Human Biology Research Ethics Committee.  Informed 159 
written consent was obtained from all donors in accordance with the Declaration of Helsinki 160 
(HBREC.2014.07).   Known HCMV sero-positive and sero-negative donors were recruited in three 161 
age groups; Young (18 – 40 years), Middle (41 – 64 years) and Old (65+ years) were included in this 162 
study.  Volunteers being treated with oral or intravenous immunomodulatory drugs (including 163 
steroids, tacrolimus, cyclosporins, azathioprines, Mycophenolate, Methotrexate, Rituximab, 164 
Cyclophosphamide) within the last 3 months, undergoing injected Rheumatoid Arthritis treatment 165 
including anti-TNFα agents and anyone actively, or within the last 24 months, being treated with 166 
cancer chemotherapy were excluded from the study.  119 HCMV sero-positive and sero-negative 167 
donors were included in this study, the age range of the recruited donor cohort was 23 – 76 years, 70 168 
donors were female and 49 donors were male.  Further characteristics of the studied donor cohort are 169 
detailed in Table 1.  In total, a 50ml peripheral blood sample was collected from each donor, 170 
comprised of 1.2ml clotted blood, 1.2ml EDTA treated blood and 47.6ml Lithium Heparin treated 171 
blood samples. 172 
 173 
Peripheral Blood Mononuclear cell isolation 174 
Peripheral blood mononuclear cells (PBMC) were isolated from the heparinized blood samples using 175 
Lymphoprep (Axis-shield, Oslo, Norway) density gradient centrifugation. 176 
 177 
Absolute count Protocol 178 
50μl of the EDTA treated whole blood sample was transferred to Becton Dickinson Trucount tubes 179 
(BD Biosciences, Oxford, UK) and stained with a pre-mixed antibody cocktail containing CD45-180 
VioBlue, CD3-VioGreen (Miltenyi Biotec, Bisley, UK.), CD4-Brilliant Violet 605, CD8-PerCP-181 
Cy5.5, CD28-PE, CD27-APC-Cy7, CD45RA-FITC, CD25-APC and CD127-PE-Cy7 (BioLegend, 182 
San Diego, USA).  Following staining the red blood cells was lysed and the cells fixed using FACS 183 
Lysing solution (BD Biosciences).  The samples were stored at -80°C until acquisition (Hensley-184 
McBain et al., 2014).  Samples were acquired on a LSR Fortessa (BD Biosciences) along with 185 
Fluorescence Minus One (FMO) controls using FACS Diva software (BD Biosciences).   Samples 186 
were then analyzed using FlowJo software (Treestar, Oregon, USA), firstly the trucount bead 187 
population was identified and then the trucount bead negative population (i.e. cells) were analyzed by 188 
gating for single cells, then CD45
hi
 lymphocytes, CD3+ T cells, CD4+ and CD8+ expressing cells.  189 
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The CD4+ and CD8+ T cell populations were further subdivided into 4 memory populations defined 190 
by expression of CD27 and CD45RA, and 4 differentiation populations defined by expression of 191 
CD27 and CD28 were identified and in CD4+ T cells a Treg population defined as CD25
hi
 and 192 
CD127
lo
 were identified, gate and quadrant positions were identified using the FMO controls.  A 193 
representative gating strategy and the formula used to calculate the absolute cell counts is illustrated 194 
in Sup. Fig. 1, the event number for all populations, and trucount beads were exported to an excel 195 
sheet where the number of cells per μl of blood for each T cell subset was calculated according to 196 
manufacturer instructions. 197 
 198 
HCMV IgG Antibody levels Protocol 199 
HCMV sero-status was confirmed using serum from the clotted blood sample and HCMV IgG levels 200 
determined using an IgG enzyme-linked immunosorbent (EIA) assay, HCMV Captia (Trinity 201 
Biotech, Didcot, UK) following manufacturer’s instructions, on serum derived from clotted blood 202 
samples.  The EIA assay is semi-quantitative, containing negative, positive and calibrator controls 203 
which allow the computation of an Immune Serum Ratio (ISR) value for the amount of HCMV IgG 204 
present in the sample.  In addition to the manufacturer controls and quality control protocols, a 205 
known positive serum sample was also run to check inter-assay variability was acceptable. 206 
 207 
HCMV ORF peptide mixes 208 
8 HCMV ORF encoded proteins (UL55 (gB), UL82 (pp71), UL122 (IE2), UL123 (IE1), US3, 209 
UL138, US28 and UL111A(vIL-10)) were selected and peptide libraries comprising consecutive 210 
15mer peptides overlapping by 10 amino acid were synthesized by ProImmune PEPScreen (Oxford, 211 
UK) from sequences detailed in the Sylwester et. al. study (Sylwester et al., 2005).  A further 3 212 
HCMV ORF encoded proteins (UL83 (pp65), UL144 (which incorporated known strain variants) and 213 
LUNA (UL81-82as)) 15mer peptide libraries were synthesized by JPT Peptide Technologies GmbH 214 
(Berlin, Germany).  The individual lyophilized peptides from each ORF library were reconstituted 215 
and used as previously described (Jackson et al., 2014). 216 
 217 
Depletion of CD4+ and CD8+ T cells from PBMC 218 
PBMC were depleted of either CD4+ or CD8+ T cells by MACS using anti-CD4+ or anti-CD8+ 219 
direct beads (Miltenyi Biotech), according to manufacturer's instructions, and separated on either LS 220 
columns (Miltenyi Biotech) or by using an AutoMACS Pro (Miltenyi Biotech). Efficiency of 221 
depletion was determined by staining cells with a CD3-FITC, CD4-PE and CD8-PerCPCy5.5 222 
antibody mix (all BioLegend) and analyzed by flow cytometry. Depletions performed in this manner 223 
resulted in mean 3.8% residual CD8+ T cells and 8.6% residual CD4+ T cells (from n=61 donors). 224 
 225 
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Dual FLUOROSPOT assays 226 
2 x 10
5
 PBMC depleted of either CD8+ or CD4+ T cells suspended in X-VIVO 15 (Lonza, Slough, 227 
UK) supplemented with 5% Human AB serum (Sigma Aldrich) were incubated in pre-coated 228 
Fluorospot plates (Human IFNγ and IL-10 FLUOROSPOT (Mabtech AB, Nacka Strand, Sweden) ) 229 
in triplicate with ORF mix peptides (final peptide concentration 2µg/ml/peptide) and an unstimulated 230 
and positive control mix (containing anti-CD3 (Mabtech AB), Staphylococcus Enterotoxin B (SEB), 231 
Phytohaemagglutinin (PHA) and Pokeweed Mitogen (PWM) and Lipopolysaccharide (LPS) (all 232 
Sigma Aldrich)) at 37ºC in a humidified CO2 atmosphere for 48 hours.   The cells and medium were 233 
decanted from the plate and the assay developed following the manufacturer’s instructions.  234 
Developed plates were read using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and 235 
counted using AID EliSpot v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany) using 236 
distinct counting protocols for IFNγ and IL-10 secretion.  Donor results were discounted from further 237 
analysis if there was greater than 1000 spot forming units (sfu) background secretion of IFNγ or IL-238 
10 in the unstimulated wells, additionally the sfu response in the positive control wells had to be at 239 
least 100sfu (IFNγ) or 50sfu (IL-10) greater than the background sfu.  All data were then corrected 240 
for background cytokine production and the positive response cut-off for IFNγ and the IL-10 241 
responses was determined by comparing the distribution of the responses from HCMV sero-positive 242 
and sero-negative donors to all HCMV proteins and the positive control.  This analysis determined 243 
that the positive response for IFNγ and IL-10 was greater than 100sfu/million, this threshold is 244 
indicated in Figures 3A, 4A and 5A (dashed line). 245 
 246 
Measurement of HCMV DNAemia in whole blood 247 
A 1ml EDTA treated whole blood sample was stored at -20°C for each donor.  DNA was isolated 248 
from the whole blood sample using the QIAamp DNA Blood Midi Kit (Qiagen, Manchester, UK) 249 
following the manufacturer’s instructions.  Extracted DNA samples were stored at -20°C until 250 
required.  The detection of HCMV by Real Time Quantitative PCR method using the StepOne Real-251 
Time PCR system (Applied Biosystems, ThermoFisher Scientific) was performed using a method 252 
adapted from (Mattes et al., 2005).  Real-time amplification of HCMV DNA used glycoprotein B-253 
specific primers, (5’-GAGGACAACGAAATCCTGTTGGGCA-3’ [gB1] and 5’-254 
GTCGACGGTGGAGATACTGCTGAGG-3’ [gB2] (Fox et al., 1995)), and detection with a 255 
TaqMan probe (5’ 6-FAM- CAATCATGCGTTTGAAGAGGTAGTCCA-BHQ1 3’ [gBP3] (Mattes 256 
et al., 2005)) mixed with ABI Universal Mastermix (Applied Biosystems, ThermoFisher Scientific), 257 
the final assay volume was 25µl, which includes a 5µl donor or control sample.   PCR cycling 258 
conditions were 2 min at 50°C, 10 min at 95°C and 45 cycles of 15 s at 95°C and 60 s at 60°C, all 259 
donor samples were screened in duplicate with a high (50 000 copies/ml) and low (500 copies/ml) 260 
positive control samples (whole EDTA treated blood spiked with HCMV genomes from the World 261 
Health Organization (WHO) international standard (Fryer et al., 2010) (National Institute for 262 
Biological Standards and Control (NIBSC), Potters Bar, UK)),  run in triplicate.  Samples with 263 
detectable HCMV DNA were repeated in triplicate in a real-time amplification including a standard 264 
curve in triplicate of 1 – 104 HCMV genomes (WHO International Standard) in addition to the high 265 
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and low positive controls.  The HCMV DNA load was calculated using the StepOne Software 266 
(Applied Biosystems, ThermoFisher Scientific) and reported as HCMV copies/ml blood.   267 
 268 
Latent Viral Load Digital PCR 269 
CD14+ Monocytes were extracted using CD14+ Magnetic beads and MS columns (Miltenyi Biotec) 270 
from PBMC isolated from 20ml of heparinized Peripheral Blood in a HCMV clean facility.  The 271 
monocytes were enumerated, dry pelleted and stored at -80°C prior to DNA extraction.  DNA was 272 
extracted from the cell pellet in a 1:1 mixture of PCR solutions A (100mM KCl, 10mM Tris-HCl 273 
pH8.3 and 2.5mM MgCl2) and B (10mM Tris-HCl pH8.3, 2.5mM MgCl2, 1% Tween 20, 1% Nonidet 274 
P-40 and 0.4mg/ml Proteinase K) at a final concentration equivalent to 10000 cells/µl, for 60 min at 275 
60°C followed by a 10 min 95°C incubation (Roback et al., 2001), extracted DNA samples were 276 
stored at -80°C until required.  Measurement of HCMV DNA in extracted CD14+ cells was assessed 277 
using a droplet digital PCR method (Parry et al., 2016).  Using the QX200 droplet digital PCR 278 
system (Bio-rad, Watford, UK) a reaction mixture containing 2µl of donor CD14+ DNA (equivalent 279 
to 20000 cells) or positive control sample was mixed with PCR grade water, 2xddPCR supermix for 280 
probes (Bio-rad), FAM labeled HCMV primer and probe (from Human CMV HHV5 kit for qPCR 281 
using a glycoprotein B target, PrimerDesign, Southampton, UK) and HEX labeled RPP30 copy 282 
number assay for ddPCR (Bio-rad).  Droplets were generated with droplet generation oil (Bio-rad) in 283 
the QX200 droplet generator (Bio-rad), then the sample was loaded into a 96 well PCR plate 284 
(Eppendorf, Stevenage, UK), sealed with a PX1 PCR Plate sealer (Bio-rad) and PCR amplification 285 
was performed using a C1000 Touch Thermocycler (Bio-rad), for 10 min at 95°C followed by 40 286 
cycles of 30 s at 94°C and 60s at 60°C.  Following PCR amplification the PCR plate was loaded onto 287 
the QX200 Droplet Reader (Bio-rad) where the presence or absence of PCR product in each droplet 288 
was read and analyzed by QuantaSoft software (Bio-rad) which gives the result of the number of 289 
virus copies per µl of PCR reaction.  All donor CD14+ DNA samples were run in either 290 
quadruplicate or triplicate.  The RPP30 copy number primer probe enabled the determination of the 291 
cell number included in the reaction and the HCMV viral load number was adjusted according to this 292 
and expressed as HCMV copies per million CD14+ cells. 293 
Statistics 294 
Statistical analysis was performed using GraphPad Prism version 6.00 for Windows (GraphPad 295 
Software, San Diego, CA, USA). Correlation was assessed by Pearson or Spearman correlation 296 
according to the distribution of the data.   Multiple data sets groups were compared using a 1 way 297 
ANOVA Kruskall-Wallis test with post hoc Dunn’s multiple comparisons or selected Mann Whitney 298 
U comparisons using an adjusted p value (p≤0.05/n comparisons) to correct for multiple testing false 299 
discovery.  300 
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Results 301 
Characterization of the ARIA Study Donor Cohort 302 
To determine whether long-term carriage of HCMV alters the HCMV specific T cell response, with 303 
respect to cytokine secretion or state of T cell differentiation,  and whether any identified changes 304 
impact on latent HCMV viral carriage and/or levels of HCMV IgG, we designed an age cross-305 
sectional study.  Donors were placed into 3 age groups: Young (age ≤ 40 years), Middle aged (age 41 306 
– 64 years) and Old (age ≥ 65 years) and also grouped on the basis of their HCMV sero-status.  307 
Potential donors were excluded from the study if they were currently taking, or had taken in the 308 
previous 3 months, any immunomodulatory or monoclonal antibody treatments or if they were 309 
currently cancer sufferers or had any form of cancer in the previous 24 months.  In total, 119 310 
individuals from the 3 age groups were included in this analysis: age range, virological and 311 
immunological parameters (HCMV IgG levels, HCMV DNA copies/ml whole blood and the 312 
CD4:CD8 Ratio) for the donor cohort are detailed in Table 1.  Correlation of the levels of HCMV 313 
IgG (ISR) (summarized for the 3 age groups in Table 1) within HCMV sero-positive (HCMV+ve) 314 
donors with age did not show a significant accumulation with age (Pearson r=0.1012, (95% CI: -315 
0.0923, 0.2873), p=0.3043).  Neither was there a significant decrease in the CD4:CD8 ratio within 316 
the HCMV+ve donor group with age (Spearman rs=0.08563, (95% CI:-0.1135, 0.2781), p=0.3851).    317 
The composition of the CD8+ and CD4+ T cell compartments, in whole blood isolated directly ex 318 
vivo, were enumerated and compared between donor age and HCMV sero-status.  Figure 1 319 
summarizes the impact of increasing age on T cell numbers in the entire donor cohort.  This analysis 320 
shows that both CD8+ and CD4+ T cell numbers significantly decrease with age (Figure 1B 321 
Spearman rs=-0.255, p=0.005 and Figure 1D Spearman rs=-0.207, p=0.024 respectively) which was 322 
likely due to the significant loss of naïve CD8+ and CD4+ T cells (Figures 1C and 1E) with no 323 
corresponding increase in numbers of memory T cell populations (Supplementary Figure 2).  324 
Enumeration of CD4+ T regulatory cells present in the peripheral blood of all donors, based on the 325 
expression of CD127 and CD25 (Hardy et al., 2013), showed that there was no effect of age on the 326 
size of this cell population (Figure 1F).  When comparing the impact of HCMV infection, in donors 327 
of all ages, on the numbers of differentiated T cell subsets, we observed a significant expansion of the 328 
effector memory (TEM – CD27-CD45RA-) population in both CD8+ (Figure 2B) and CD4+ T cells 329 
(Figure 2D).  Within CD8+ T cells only, we also saw a significant increase in the highly 330 
differentiated TEMRA (CD27-CD45RA+) and CD27-CD28- (LATE) populations (Figures 2B and 2C).  331 
A key component of the IRP which is associated with HCMV infection is the inversion of the 332 
CD4:CD8 ratio (<1), we only saw this phenomenon in 10% of the sero-positive donor group.  333 
However we observed that overall the CD4:CD8 ratio was significantly decreased in HCMV sero-334 
positive donors compared to sero-negatives (Figure 2G). 335 
Magnitude and Breadth of T cell responses to HCMV Proteins remain stable with donor age. 336 
To establish whether HCMV latent and lytic protein specific T cells are maintained and are 337 
functional during long term carriage of the virus, we analyzed T cell responses to 5 viral genes 338 
known to be expressed during HCMV latent infection; UL138 (Goodrum et al., 2007), LUNA (Bego 339 
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et al., 2005; Reeves and Sinclair, 2010), US28 (Beisser et al., 2001), UL111A (vIL-10) (Jenkins et 340 
al., 2004) and UL144 (Poole et al., 2013), two of which (UL138 and LUNA), we have previously 341 
shown elicit both an IFNγ and IL-10 CD4+ T cell response (Mason et al., 2013). We also wanted to 342 
measure the range of T cell responses in a large donor cohort to a number of viral proteins expressed 343 
during lytic infection; we have previously identified both CD4+ and CD8+ T cells producing IFNγ 344 
from many donors to 6 HCMV lytic proteins pp65, IE1, IE2, gB, pp71 and US3 (Jackson et al., 2014; 345 
Jackson et al., 2017).  Using Fluorospot methodology, we were able to measure CD8+ T cell IFNγ 346 
responses and both IFNγ and IL-10 CD4+ T cell responses to overlapping peptide pools of these 11 347 
HCMV proteins.  Both HCMV sero-positive and sero-negative donors of all ages were included in 348 
these antigen specific screens and, after discounting samples following quality control (high 349 
spontaneous cytokine spot forming unit (sfu) counts in unstimulated wells or failure of positive 350 
control stimulation), 98 donors were included in the CD8+ T cell analysis, 99 donors in the CD4+ T 351 
cell IFNγ analysis and 73 donors in the CD4+ T cell IL-10 analysis.   352 
Figure 3 summarizes the results from the screen of 98 donors for CD8+ IFNγ T cell responses. A 353 
majority of the HCMV sero-positive donors analyzed had an above threshold (100 sfu/million) CD8+ 354 
IFNγ T cell response to the 6 lytic  proteins analyzed as well as responses to the latency associated 355 
proteins UL144 and US28 proteins (Figure 3A).  We noted positive CD8+ T cell responses to LUNA 356 
(31.8% of donors) and UL138 (29.6% of donors), which whilst present in our previous study, using 357 
an enzymatic ELISPOT method, were below the positive response threshold (Mason et al., 2013) 358 
because this was a much less sensitive detection system.  The frequency of individual donors who 359 
produced CD8+ T cell responses to 1 or more HCMV proteins is presented as pie charts for the lytic 360 
expressed proteins (Figure 3B), latency associated proteins (Figure 3E) and for all HCMV proteins 361 
(Figure 3H).  These analyses shows that a majority of the donors produced a response to 5 or 6 lytic 362 
proteins (51.6% - blue and deep pink segments Figure 3B), that 29.7% of the donor cohort responded 363 
to 4 or 5 of the latency associated proteins (green and blue segments Figure 3E) and, overall, 47.2% 364 
of the cohort responded to 8 or more HCMV proteins (orange, dark green, teal and purple segments, 365 
Figure 3H).  The broad range of responses to lytic, latent and all HCMV proteins observed were also 366 
maintained with age (Figures 3C, 3F and 3I respectively).  An analysis of  whether increasing age 367 
alters the magnitude of the CD8+ T cell IFNγ response to HCMV revealed no impact on the 11 368 
individual proteins (data not shown) or  the summed responses to lytic (Figure 3D), latent (Figure 369 
3G) or all (Figure 3J) HCMV proteins examined.   370 
We also examined the CD4+ T cell responses of the donor cohort to the same 11 HCMV proteins in 371 
99 donors.  As observed for the CD8+ T cell responses, the majority of the HCMV seropositive 372 
donor cohort produced an above threshold IFNγ response to all the lytic expressed proteins but also 373 
latency-associated UL144 and US28 (Figure 4B).  The responses to the lytic expressed proteins by 374 
CD4+ T cells  have already been reported in a sub-set of this donor cohort (Jackson et al., 2017), 375 
however the observation that both UL144 and US28 proteins induce T cell responses in the majority 376 
of HCMV sero-positive donors has not previously been reported.  Only 29.6% of the donor cohort 377 
examined produced an above threshold CD4+ IFNγ response to UL138, LUNA and vIL-10 latency 378 
associated proteins; this is a similar frequency to that seen in the CD8+ T cell compartment and not 379 
dissimilar to the percentage of responding donors for UL138 and LUNA CD4+ T cell responses 380 
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previously reported in a small scale study (Mason et al., 2013).  The ability of individual donors to 381 
mount CD4+ IFNγ responses to multiple HCMV proteins is summarized as pie charts (Figure 4B, 382 
4E, 4H).  In contrast to the CD8+ T cell IFNγ response routinely seen to 5 or 6 lytic proteins, fewer 383 
donors were capable of mounting responses to 5 or 6 of the lytic expressed HCMV proteins (43.9% - 384 
blue and deep pink segments, Figure 4B). This trend was maintained in response to the latent proteins 385 
(22% responding to 4 or 5 proteins – green and blue segments, Figure 4E) and, overall, only 33% of 386 
the donor cohort responded to 8 or more of the examined HCMV proteins (Figure 4H - orange, dark 387 
green, teal and purple segments).  Despite this lower proportion of HCMV sero-positive donors 388 
responding to many HCMV proteins, the overall breadth of the CD4+ IFNγ T cell response remained 389 
stable with increasing donor age which shows that there was no significant increase or decrease in the 390 
number of proteins an individual responded to within the lytic (Figure 4C) or latent group of proteins 391 
(Figure 4F) or to all 11 proteins examined (Figure 4I).  Also, we did not observe an effect of donor 392 
age on the magnitude of the response to the individual HCMV proteins (data not shown) or to the 393 
summed responses to the 6 lytic proteins (Figure 4D), 5 latent proteins (Figure 4G) or to the summed 394 
response of all 11 proteins (Figure 4J).   395 
We next examined the ability of CD4+ T cells to produce cIL-10 following stimulation with our 11 396 
candidate HCMV proteins.  Cellular IL-10 levels were measured in 73 HCMV donors from the 397 
cohort (these donors having passed the quality control thresholds outlined in the methods).  Although 398 
we have already shown that lytically expressed proteins pp71 and US3 can induce cIL-10 production 399 
by CD4+ T cells in a small sub-set of this donor cohort (Jackson et al., 2017), in this larger donor 400 
cohort pp71 (38.8%), US3 (32.8%) and pp65 (23.8%) are the most common lytic proteins to trigger 401 
an above threshold cIL-10 CD4+ T cell response.  The latency associated proteins, US28 (34.3%), 402 
LUNA (31.3%) and UL138 (26.8%) also frequently induced a CD4+ specific cIL-10 response in this 403 
donor cohort.  In contrast to the ability of donors to produce IFNγ T cell responses to multiple 404 
HCMV proteins, a positive cIL-10 response to any one of the 11 HCMV proteins examined was 405 
absent in 19 of 67 seropositive donors (grey segment – Figure 5H) and no donors produced responses 406 
to more than 9 of the 11 HCMV proteins.  When examining the response to the 6 lytic proteins, about 407 
half of the 67 donors (49.3%) did not produce a cIL-10 response (grey segment – Figure 5B).  408 
Despite this more limited breadth of the response, 70% of the donors examined produced an above 409 
threshold cIL-10 response to 1 or more HCMV protein.  The ability of an individual donor to produce 410 
a cIL-10 response to HCMV proteins was not affected by age (Figures 5C, 5F, 5I) and neither was 411 
the magnitude of the responses to each of the 11 HCMV proteins (data not shown).  The relationship 412 
of the total cIL-10 responses, for each donor, to the 6 lytic proteins (Figure 5D), 5 latent proteins 413 
(Figure 5G) and all 11 proteins (Figure 5J) was also stable with donor age.  Overall, the data 414 
presented show that the breadth and magnitude of the IFNγ and cIL-10 HCMV specific T cell 415 
responses, within this donor cohort, do not show any impact of either increasing donor age or 416 
putative long term carriage of the virus on these HCMV specific T cell responses. 417 
  418 
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CD4+ T cells specific for LUNA, UL138, pp71, US3 and US28 proteins are more frequently 419 
biased towards expression of cIL-10 than IFN γ and this was not affected by donor age. 420 
Using the fluorospot technology, we were able to ask whether CD4+ T cell responses to our 421 
candidate HCMV proteins was dominated by either IFNγ or IL-10 secretion or whether it was 422 
comprised of cells that secrete both cytokines.  Figure 6 shows the relative cytokine composition of 423 
the CD4+ T cell response to each of the 11 HCMV proteins examined for donors who generated an 424 
above threshold response (> 100 sfu/million) for either cytokine.  Overall, we found that IFNγ and 425 
cIL-10 are generally produced by distinct populations of CD4+ T cells, as dual secretors were very 426 
rare (red bars – Figure 6).  The CD4+ T cell responses to UL144 (Figure 6D), gB (Figure 6J), pp65 427 
(Figure 6H), IE1 (Figure 6K) and IE2 (Figure 6I) proteins were dominated by IFNγ secretion.  In 428 
contrast, the donor cohort responses to the proteins UL138 (Figure 6C), LUNA (Figure 6B), US28 429 
(Figure 6A), vIL-10 (Figure 6E), pp71 (Figure 6F) and US3 (Figure 6G) showed more cIL-10 430 
secretors (white spotted bars).  Although there was no significant change in the magnitude of the 431 
CD4+ T cell IL-10 response to HCMV proteins with age (summarized Figure 5), we were interested 432 
to see if there was a change in the proportion of IFNγ and IL-10 secretion by CD4+ T cells within 433 
individuals during long term viral carriage.  The data presented in figure 6 are arranged with donor 434 
age along the x-axis and does not show any obvious changes in the composition of the positive CD4+ 435 
T cell response.  Analysis of the proportion of donors in which the majority of the CD4+ T cell 436 
responses was secretion of cIL-10  (i.e. greater than 50% of the total CD4+ T cell response of the 437 
individual to each HCMV protein) revealed that for LUNA 48.5% of responding donors had a 438 
dominant cIL-10 response (Sup. Figure 3A).  UL138, pp71, US3 and US28 also elicited a greater 439 
than 50% IL-10 response in more than a third of the donor cohort (42.8%, 38.4%, 34% and 33.3% 440 
respectively; Sup. Figure 3A).  When looking at the breadth of the cIL-10 dominant responses with 441 
donor age, there was no significant increase in the breadth of HCMV proteins an individual produced 442 
a majority cIL-10 response towards for all proteins (Sup. Figure 3B), lytic proteins (Sup. Figure 3C) 443 
or latent associated proteins (Sup. Figure 3D).   444 
 445 
The magnitude of latent HCMV DNA load in CD14+ monocytes is not affected by donor age in 446 
the ARIA Cohort. 447 
In addition to assessing the effect of increasing age on the T cell response to HCMV lytic and latent 448 
expressed proteins, the other principle aim of this study was to determine if there was an age-related 449 
effect on latent viral load.  Consequently, we screened whole blood of all donors in the study for the 450 
presence of HCMV DNA using a quantitative real time PCR assay.  No viral DNA was detectable in 451 
the 14 HCMV sero-negative donors and of the 105 HCMV sero-positive donors, viral genome was 452 
only detected in 1 of these (274 copies/ml whole blood).   The donor with detectable HCMV in 453 
whole blood also had an inverted CD4:CD8 ratio and above average numbers of differentiated 454 
memory CD8+ T cells, data summarized in supplementary Figure 4.  During latent HCMV infection, 455 
virus is known to reside in CD34+ hematopoietic stem cells and derivative CD14+ monocytes 456 
(Reeves et al., 2005).  Using a sensitive digital droplet PCR approach (Parry et al., 2016), we 457 
quantified the number of copies of HCMV present in isolated CD14+ monocytes from all donors.   In 458 
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total we assessed 108 HCMV sero-positives and negatives for HCMV DNA present in CD14+ cells; 459 
of these, no copies of viral genome were detected in the 14 HCMV sero-negative donors.  We did, 460 
however, detect HCMV genomes in 43 of 94 (45.7%) of CD14+ monocytes from HCMV sero-461 
positive donors (51 of 94 were below the level of detection of this assay, 1 genome in 60 000 cells); 462 
the latent viral load (copies HCMV/million CD14+ cells) for the 94 sero-positive donors, relative to 463 
donor age, is summarized in figure 7.  Within this ARIA donor cohort, we did not observe a 464 
significant relationship between age and the magnitude of the latent viral load.  465 
 466 
High Latent viral loads in CD14+ Monocytes were associated with both increased breadth and 467 
frequency of IFNγ secreting HCMV specific T cells. 468 
HCMV is latently carried in CD34+ hematopoietic progenitor cells and subsequently in the periphery 469 
by monocyte derivatives from these cells (Reeves and Sinclair, 2013). Virus reactivation from these 470 
myeloid lineage cells would activate HCMV specific T cells and could drive increased frequencies, 471 
as well as potentially seeding more cells in the latent reservoir.  Theoretically, increased frequency of 472 
latently infected cells could result in increased virus reactivation events, potentially resulting in 473 
induction of more T cell stimulation and, possibly, an increase in HCMV specific antibody levels 474 
during life-long persistence.   Consequently, we assessed whether there was an association between 475 
HCMV specific IgG levels and latent viral load, but these measures were unrelated (data not shown).  476 
We then assessed whether there was an association between the latent viral load and the CD8+ and 477 
CD4+ T cell responses to the individual HCMV proteins as well as to the magnitude and breadth of 478 
the total responses of each donor.  We did not observe an association between latent load and the cIL-479 
10 CD4+ response and there was only a significant association between the magnitude and breadth of 480 
the CD4+ IFNγ response to the subset of 6 lytic proteins and increased latent viral load (data not 481 
shown).  There was a significant association with the summed total of the CD8+ T cell response to 482 
lytic (Figure 8B), latent (Figure 8D) and all proteins (Figure 8F).  Also, high viral copy latent load 483 
correlated significantly to the breadth of the CD8+ T cell responses to lytic (Figure 8A) and all 484 
HCMV proteins (Figure 8E).        485 
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Discussion 486 
The aims of this study were to determine whether HCMV specific CD4+ T cells secreting cIL-10 487 
increase with age and long-term viral carriage and to determine whether there are changes in breadth 488 
and frequency of the IFNγ secreting T cell response to HCMV infection in healthy older donors.  We 489 
also wanted to measure the latent viral load of HCMV DNA in a large donor cohort for the first time 490 
and assess whether donors aged over 65 years manifested changes in immune cell numbers indicative 491 
of immunosenescence.  Using an age cross-sectional study methodology, we recruited a donor cohort 492 
spanning 6 decades (23 – 78 years) and measured virological and immunological parameters.  The 493 
donors were recruited by the Cambridge Bioresource from their Biobank of volunteers who live 494 
predominantly in areas local to Cambridge and the East Anglian Region of the United Kingdom 495 
(UK).  Donors were recruited based on HCMV sero-status and by excluding donors suffering from 496 
immune altering illnesses or under treatment for these conditions, such that all participants could be 497 
safely considered to be generally healthy.   498 
We analyzed the CD4+ and CD8+ T cell compartments in peripheral blood and observed a loss of 499 
naïve CD4+ and CD8+ T cell numbers as well as a corresponding loss of total CD4+ and CD8+ T 500 
cell numbers with increasing age.  The age-related loss of naïve T cells numbers is a well-established 501 
phenomenon due to the involution of the thymus and decreased T cell output (Lynch et al., 2009) and 502 
has been observed in most studies of ageing populations (Weltevrede et al., 2016).  In our study, 503 
there was no accumulation of memory T cell populations (measured in absolute numbers) within this 504 
cohort, which has also been observed in other studies when using absolute numbers (Chidrawar et al., 505 
2009; Wertheimer et al., 2014).  However, when expressed as a percentage of the CD8+ T cell 506 
compartment, there was a significant age-related accumulation of differentiated TEMRA (CD27-507 
CD45RA+) and Late stage (CD27-CD28-) memory cell populations as has been previously reported 508 
(Weltevrede et al., 2016).   It is likely that the increase in percentage (relative frequency) of 509 
differentiated memory T cell populations previously reported in aged cohorts, was due to the 510 
decrease in the absolute size of the overall CD8+ T cell compartment, which results in an increase in 511 
the proportion of memory cells even if the absolute numbers do not increase (Chidrawar et al., 2009; 512 
McElhaney and Effros, 2009; Wertheimer et al., 2014).   513 
Previous investigations into the impact of HCMV persistence on immunosenescence in older people 514 
have reported a range of immune parameters and HCMV specific markers altering with age.  These 515 
include the Immune Risk Phenotype (IRP), defined by a collection of markers which, taken together, 516 
were suggested to be indicative of increased mortality in the elderly and which included an inversion 517 
of the CD4:CD8 ratio, expansion of CD8+ CD28
null
 and CD8+ TEMRA memory T cells and HCMV 518 
sero-positivity (Olsson et al., 2001; Wikby et al., 2002; Hadrup et al., 2006; Strindhall et al., 2013).  519 
There have also been reports of HCMV specific IgG levels increasing in older donors (McVoy and 520 
Adler, 1989; Alonso Arias et al., 2013; Parry et al., 2016) as well as accumulation of HCMV specific 521 
T cells with age (summarized in (Weltevrede et al., 2016)).  Similarly, it has been suggested that 522 
there is an age-related increase in levels of HCMV DNA in blood (Furui et al., 2013), urine (Stowe et 523 
al., 2007) and an increase in latent viral genome copy number in CD14+ cells of donors aged over 70 524 
years (Parry et al., 2016).   Overall, as our donor cohort exhibited a normal ageing immune 525 
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phenotype, we examined the impact of HCMV sero-positivity on T cell memory phenotype within 526 
the study group.  There were no significant differences in naïve T cell numbers between aged HCMV 527 
sero-positive compared to aged HCMV sero-negative donors in our cohort and we only observed an 528 
inverted CD4:CD8 ratio in 10% of the sero-positive donor cohort; donors exhibiting this phenotype 529 
were distributed throughout the age categories.  We did see an increase in the numbers of 530 
differentiated T cells in HCMV sero-positive donors of all ages compared to sero-negatives, 531 
confirming that our study participants have a similar T cell phenotype to that observed in many 532 
previous studies of HCMV infection (Weltevrede et al., 2016).  There was, however, no association 533 
between increasing donor age and higher levels of HCMV IgG nor was there an increase in the 534 
breadth and frequency of the HCMV specific T cell IFNγ response or CD4+ cIL-10 response to the 535 
eleven HCMV proteins examined within the study group.   We also did not detect increased copies of 536 
latent HCMV genome in CD14+ monocytes of our older donors.   The separate impact of HCMV 537 
infection from ageing on the differentiation of T cells has been observed in other population studies 538 
(Lelic et al., 2012; Furman et al., 2015) and the kidney transplant primary infection model and 539 
reports from primary infection has shown a rapid acquisition of a more differentiated T cell 540 
phenotype in the months following initial infection (Gamadia et al., 2003; Day et al., 2007; Miles et 541 
al., 2007; Lilleri et al., 2008).   Furthermore, we observed a significant association between high 542 
latent viral loads and higher frequency HCMV specific CD8+ T cell responses, which was again 543 
irrespective of donor age.  These observations alongside the increased numbers of differentiated 544 
memory T cells suggest that, within this healthy donor cohort, it is HCMV infection, rather than the 545 
age of the donor, which leads to increased differentiation of the T cell population and expansion of 546 
HCMV specific T cells.    547 
Work on donor cohorts from different geographical locations have reported different findings from 548 
the original Swedish studies which described the IRP (Olsson et al., 2001; Wikby et al., 2002; 549 
Hadrup et al., 2006; Strindhall et al., 2013), these have included  a lack of “inflation” of HCMV 550 
specific T cells with age despite high HCMV sero-prevalence in the aged  donor groups (Colonna-551 
Romano et al., 2007) and the association of a naïve T cell phenotype in HCMV sero-positive old 552 
people with increased morbidity in Belgium (Adriaensen et al., 2015).   HCMV sero-prevalence 553 
varies depending on geographical location and socio-economic status (Gandhi and Khanna, 2004; 554 
Crough and Khanna, 2009); in the developed world between 30 – 70% of populations are HCMV 555 
sero-positive, with acquisition of the virus increasing with age (Cannon et al., 2010). In contrast, in 556 
developing countries, sero-prevalence can be higher than 90% with acquisition of the virus 557 
commonly occurring in early childhood (Miles et al., 2007; Cannon et al., 2010).  Consequently, the 558 
disparate observations reported as consequences of HCMV infection in different aged donor cohorts 559 
may be a result of geography as well as other biological parameters such as exposure to infectious 560 
diseases, vaccination history and the current health of the participants.  It has also been shown in 561 
other studies of very old cohorts that increased HCMV IgG levels and differentiated CD4+ T cells 562 
are associated with elderly individuals in poor health (Vescovini et al., 2010) and there are also a 563 
number of studies associating HCMV sero-positivity and higher HCMV IgG titers with poor 564 
outcomes from cardiovascular disease (Simanek et al., 2011; Gkrania-Klotsas et al., 2012; Savva et 565 
al., 2013; Spyridopoulos et al., 2016).  Our view is that, in some cohorts that have been studied, aged 566 
donors suffering from e.g. heart disease, cancer or neurodegenerative disorders may not control virus 567 
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efficiently leading to increased HCMV IgG levels or HCMV DNAemia and concomitant increased 568 
numbers of differentiated memory T cell populations and an inverted CD4:CD8 ratio thereby 569 
confounding some studies.    570 
One of our aims was to address the production of cIL-10 by HCMV specific CD4+ T cells within a 571 
large donor cohort in order to assess how prevalent the production of this suppressive cytokine is by 572 
HCMV antigen specific T cells and whether this response increases in older donors.   Evidence from 573 
mouse models of MCMV infection have shown that production of cIL-10 can result in reduced viral 574 
clearance and a reduction in production of IFNγ by MCMV specific T cells (Jost et al., 2014; 575 
Clement et al., 2016).  This could provide an explanation for the observation that, despite a functional 576 
immune response preventing overt HCMV mediated disease, older donors have detectable HCMV 577 
DNA in blood and urine (Stowe et al., 2007; Furui et al., 2013).  In some HCMV studies, increases in 578 
inducible regulatory CD4+ T cells have been reported in older people with this being associated with 579 
vascular pathology in these individuals (Terrazzini et al., 2014).  Similarly, it has also been suggested 580 
that the HCMV specific CD4+ CD28-CD27- T cell population, reported as expanded in HCMV 581 
seropositive older people (Fletcher et al., 2005) contains a T regulatory population characterized by 582 
FoxP3 and CD25
hi
 expression (Tovar-Salazar et al., 2010).  As already discussed, there was no 583 
accumulation of the cIL-10 CD4+ T cell response with increasing donor age in this cohort; we were 584 
also interested to see if there was a shift in the bias of the responding CD4+ T cells to individual 585 
HCMV proteins from IFNγ to IL-10 or vice-versa.  The results confirmed our previous observation 586 
that the production of cIL-10 by CD4+ T cells is more likely to be in response to latency associated 587 
proteins (Mason et al., 2013); in this cohort almost 50% and 40% of donors produced a majority cIL-588 
10 response to stimulation by the LUNA and UL138 peptide pools respectively regardless of donor 589 
age. Similarly, other latency associated proteins included in this study, US28 and vIL-10, also 590 
showed a number of donors biased towards cIL-10 production, which is in contrast to the response 591 
towards many of the lytically expressed proteins included in this study.   592 
The use of the digital droplet PCR (ddPCR) protocol (Parry et al., 2016) has, enabled better 593 
quantification of the levels of latent HCMV genomes in the CD14+ cell compartment.  We were able 594 
to detect and quantify latent HCMV genomes in 45.7% of examined HCMV sero-positive donors 595 
comparing favorably to the 36% detection rate in HCMV positive donors described recently by 596 
ddPCR (Parry et al., 2016).  Our ability to quantify latent HCMV load in our donor cohort led to a 597 
particularly interesting observation with respect to HCMV specific T cell response.  As already 598 
noted, high copy numbers of latent HCMV detected in CD14+ monocytes significantly correlated 599 
with an increase in the breadth and magnitude of the HCMV specific CD8+ T cell response measured 600 
by IFNγ secretion.  From this result, we hypothesize that higher viral genome copy number was a 601 
result of an accumulation of reactivation events over the time, resulting in viral replication and 602 
reseeding of the latent CD34+ cellular pool; consequently this production of viral proteins stimulates 603 
and activates HCMV specific memory  T cell response leading to an increase in frequency of these 604 
cells.  The virus most likely employs its immune evasion functions to create a window of opportunity 605 
to allow reactivation from latency and the production of new virions despite the presence of a primed 606 
anti-viral immune response (Wills et al., 2015).  In older donors, uncontrolled reactivation of HCMV 607 
subsequently causing either disease or other medical complications has not been observed, and 608 
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HCMV DNA has not been routinely detected in the blood (Vescovini et al., 2004; Stowe et al., 609 
2007), apart from in a Japanese cohort study, but the DNA positive detection rate was only 4.3% of 610 
donors aged 60 – 69 years (Furui et al., 2013).  However, there is evidence that older people may not 611 
control virus replication as adequately as the young, as HCMV DNA has been detected in other 612 
bodily fluids in the old (Stowe et al., 2007).  Within this study, our exclusion criteria may have 613 
precluded recruitment of donors who had less effective control of virus replication resulting in low 614 
level virus dissemination.  In support of this conclusion, it is interesting to note that a single aged 615 
male donor with detectable HCMV DNA in whole blood did have an inverted CD4:CD8 ratio as well 616 
as an above average number of highly differentiated memory CD8+ T cell populations; they also had 617 
limited HCMV specific T cell responses to our 11 candidate HCMV proteins (Supplementary Figure 618 
4).   619 
We have demonstrated that, in an East Anglian-based donor cohort which has a typical healthy 620 
ageing profile, older HCMV sero-positive donors do not exhibit the hallmark features of the IRP, 621 
differences in the breadth and magnitude of their HCMV specific IFNγ production; or that latent viral 622 
load was affected by age.  Importantly, though we did see a significant relationship between high 623 
latent viral load and increased breadth and magnitude of the functional HCMV specific CD8+ T cell 624 
responses, latent viral load did not correlate with increased numbers of differentiated memory T cell 625 
populations or HCMV specific IgG.  This, we believe, reflects the importance of including 626 
measurement of viral load in studies on the impact of HCMV infection in older donors as opposed to 627 
inferring the impact of the virus from measuring a variety of other immune parameters as has 628 
previously occurred.  In a previous study in a Birmingham based old aged cohort, the authors 629 
observed an increase in HCMV specific T cell responses alongside, an increase in latent viral 630 
carriage in donors aged over 70 years (Parry et al., 2016). Whilst the authors do not present data 631 
correlating latent viral load with the frequency of HCMV specific T cells, we think it possible in light 632 
of our findings, that in this older cohort study, the increase in HCMV specific T cell responses in 633 
older donors could be associated with increased latent viral carriage.     634 
Detection of low level HCMV viremia in the blood of the old would be a strong indicator of a 635 
diminution of immune control, however the results from our study group and others (Vescovini et al., 636 
2004; Stowe et al., 2007) suggests this is rarely observed, probably because it would represent a 637 
significant loss of control.  However, the presence of virus in other bodily fluids e.g. saliva or urine 638 
could also indicate loss of immune control.  It should be considered that chronic low level persistent 639 
HCMV replication and an associated inflammatory environment could be important in particular old 640 
patients groups; there is epidemiological evidence that HCMV comorbidity plays a role in 641 
exacerbating cardiovascular disease (Simanek et al., 2011; Gkrania-Klotsas et al., 2012; Savva et al., 642 
2013; Spyridopoulos et al., 2016) and also with increasing impaired physical function and ill health 643 
(Vescovini et al., 2010; Haeseker et al., 2013; Adriaensen et al., 2015; Broadley et al., 2017).  Future 644 
investigations into the impact of HCMV infection in older people should also monitor latent viral 645 
carriage of the virus alongside measuring whether low level viremia is present in the blood and other 646 
bodily fluids, e.g. urine or saliva; in order to improve our understanding of the impact of HCMV 647 
infection in the elderly. 648 
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Tables 940 
  All Ages Young  
(<40 years)  
Middle  
(41-64 years)  
Old  
(>65 years)  
   HCMV +ve HCMV -ve HCMV +ve HCMV +ve HCMV +ve 
Donors  
(n) 
All 105 14  33 31 41 
M 44 5 14 14 16 
F  61 9 19 17 25 
Age (Years) 
(Mean ± S.D.) 
All 54.4 ± 15.6 51.4 ± 14.4 34.6 ± 5.1 54.5 ± 6.0 70.2 ± 3.1 
M 54.3 ± 16.1 46.2 ± 12.7 34.7 ± 5.5 53.9 ± 6.5 71.7 ± 2.8 
F  54.5 ± 15.3 54.3 ± 14.4 34.6 ± 4.8 54.9 ± 5.5 69.3 ± 2.8 
HCMV IgG (ISR) 
(Mean ± S.D.) 
All 3.78 ± 1.28 0.28 ± 0.14 3.66 ± 1.32 3.81 ± 0.99 3.85 ± 1.42 
M 3.67 ± 0.95 0.25 ± 0.10 3.15 ± 0.74 4.06 ± 0.74 3.78 ± 1.06 
F  3.86 ± 1.47 0.29 ± 0.15 4.03 ± 1.51 3.60 ± 1.12 3.90 ± 1.61 
HCMV DNAemia 
(copies/ml blood) 
(Mean ± S.D.) 
All 2.6 ± 26.7* undetected undetected undetected 6.7 ± 42.4* 
M 6.3 ± 41.0* undetected undetected undetected 17.2 ± 66.6* 
F  undetected undetected undetected undetected undetected 
CD4:8 Ratio 
(Mean ± S.D.) 
All 2.25 ± 1.61 3.60 ± 1.80 2.04 ± 0.85 1.96 ± 0.85 2.63 ± 2.29 
M 2.10 ± 1.00 4.00 ± 2.10 1.80 ± 0.70 2.00 ± 1.00 2.30 ± 1.20 
F  2.40 ± 1.90 3.40 ± 1.50 2.20 ± 0.90 1.90 ± 0.70 2.90 ± 2.80 
* HCMV DNAemia detected in n=1 old male donor 941 
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Figure Legends 943 
Table 1 – ARIA Cohort Donor Characteristics 944 
Summary of the number of donors and age ranges, serum HCMV IgG levels (Immune Status Ratio – 945 
ISR), blood HCMV DNA copies and the CD4:CD8 ratio (generated from absolute count data).   946 
Figure 1 – Impact of Ageing on T cell numbers 947 
EDTA treated whole blood was stained with a panel of phenotyping antibodies in order to enumerate 948 
CD4+ and CD8+ T cells and their subsets.  Representative dot plots from a young and old donor 949 
showing CD4+ and CD8+ T cell gates, naïve T cells subset were defined by CD27+ and CD45RA+ 950 
(TNAIVE) expression and CD4+  T regulatory cells (TREG – CD25
hi
, CD127
lo
); the number of cells/µl 951 
of whole blood present for each gated population of interest are also indicated (A).  Graphs 952 
illustrating the numbers of total CD8+ T cells (B), TNAIVE CD8+ T cells (C), total CD4+ T cells (D), 953 
TNAIVE CD4+ T cells and CD4+ TREG cells of the entire ARIA cohort (n=119) correlated to donor 954 
age.  The relationship of T cell subset numbers with donor age was analyzed using Spearman rank 955 
correlation with the results indicated on each graph (rs (95% Confidence Interval) and p value).  956 
There was a significant decrease in total and TNAIVE CD4+ and CD8+ T cells with age, CD4+ TREG 957 
numbers showed no significant difference.  958 
Figure 2 – Impact of HCMV carriage on T cell numbers 959 
EDTA treated whole blood was stained with a panel of phenotyping antibodies in order to enumerate 960 
CD4+ and CD8+ T cells and their subsets.    Representative dot plots from a HCMV sero-positive 961 
(HCMV+ve) and HCMV sero-negative (HCMV-ve) age-matched donors are illustrated showing the 962 
memory (as defined by CD27 and CD45RA expression) and differentiation level  (as defined by  963 
CD27 and CD28) phenotype of both CD4+ and CD8+ T cells; the number of cells/µl of whole blood 964 
for effector memory (TEM – CD27-CD45RA-)  CD4+ and CD8+ T cells and Intermediate (INT – 965 
CD27-CD28+) and Late (LATE – CD27-CD28-) differentiated CD8+ T cells are shown (A).  Box 966 
and whisker plots comparing cell numbers of the memory (B, D) and differentiation phenotypes (C, 967 
E) of CD8+ T cells and CD4+ T cells respectively between HCMV+ve (red) and HCMV-ve (green) 968 
donors are shown.  The differences between the two groups were analyzed by a Kruskall-Wallis one-969 
way ANOVA test with post-hoc Mann Whitney U test performed with significant results set as 970 
p≤0.015 shown on each graph.  A representative CD4 vs CD8 dot plot from the same donors with 971 
their respective CD4:CD8 ratio indicated are shown (F), the comparison of CD4:CD8 ratios for all 972 
sero-positive vs sero-negative donors are also shown (G) with the significant decrease in the 973 
CD4:CD8 ratio in HCMV positive donors indicated (Mann Whitney test).   974 
Figure 3 – Magnitude and Breadth of CD8+ T cell IFNγ response to HCMV proteins. 975 
The IFNγ secreting CD8+ T cell response to 6 HCMV proteins only expressed during lytic infection: 976 
pp65, IE2, pp71, IE1, gB, US3 and 5 HCMV latency associated proteins: UL144, US28, vIL-10, 977 
LUNA and UL138 were measured in a cohort of 91 HCMV sero-positive and 7 sero-negative donors.  978 
The production of IFNγ was measured using an IFNγ Fluorospot detection method; with the results 979 
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converted to spot forming units/million cells (sfu/million) with background counts subtracted.  The 980 
response to the lytic expressed proteins (red), latency associated (blue) and the positive control by all 981 
98 donors are summarized (A) with HCMV sero-positive donors (dark) and HCMV sero-negative 982 
donors (light) both illustrated.  The positive response threshold cut-off of 100 sfu/million is shown 983 
(dashed line) and the proportion of donors with a positive response to each HCMV protein is 984 
indicated.  The proportion of the 91 sero-positive donors producing a positive response to 1 or more 985 
of the 6 Lytic expressed proteins (B), 5 latency associated proteins (E) or all 11 HCMV proteins (H) 986 
are summarized as pie charts with the key to segments for each graph shown.  Graphs illustrating the 987 
breadth of HCMV sero-positive donors response to HCMV proteins correlated with age are 988 
illustrated for lytic expressed (C), latency associated (F) and all 11 proteins (I); also shown is the 989 
summed IFNγ response to lytic (D), latent (G) and all proteins (J) correlated with age.  Spearman 990 
rank correlation (Spearman rs (95% Confidence Intervals (CI)) and p values) results are indicated on 991 
each graph.  992 
Figure 4 – Magnitude and Breadth of CD4+ T cell IFNγ response to HCMV Proteins. 993 
The IFNγ secreting CD4+ T cell response to 6 HCMV proteins only expressed during lytic infection: 994 
pp65, IE2, pp71, IE1, gB, US3 (red) and 5 HCMV latency associated proteins: UL144, US28, vIL-995 
10, LUNA and UL138 (blue) were measured in a cohort of 91 HCMV sero-positive and 8 sero-996 
negative donors.  The production of IFNγ was measured using an IFNγ Fluorospot method; with the 997 
results converted to spot forming units/million cells (sfu/million) with background counts then 998 
subtracted.  The response to the HCMV proteins and the positive control by all 99 donors are 999 
summarized (A) with HCMV sero-positive donors (dark) and HCMV sero-negative donors (light) 1000 
both illustrated.  The positive response threshold cut-off of 100 sfu/million (dashed line) and the 1001 
proportion of donors with an above threshold response to each HCMV protein is indicated.  The 1002 
proportion of the 91 sero-positive donors producing a positive IFNγ response to 1 or more of the 6 1003 
Lytic expressed proteins (B), 5 latency associated proteins (E) or all 11 HCMV proteins (H) are 1004 
summarized as pie charts with the key to segment color for each graph shown.  Graphs illustrating 1005 
the breadth of HCMV sero-positive donors IFNγ response to HCMV proteins correlated with age are 1006 
illustrated for lytic expressed (C), latency associated (F) and all 11 proteins (I); also shown is the 1007 
summed IFNγ response to lytic (D), latent (G) and all proteins (J) correlated with age.  Spearman 1008 
rank correlation (Spearman rs (95% Confidence Intervals (CI)) and p values) results are indicated on 1009 
each graph. 1010 
Figure 5 – Magnitude and breadth of CD4+ T cell IL-10 response to HCMV Proteins 1011 
The IL-10 secreting CD4+ T cell response to 6 HCMV proteins only expressed during lytic infection: 1012 
pp65, IE2, pp71, IE1, gB, US3 (red) and 5 HCMV latency associated proteins: UL144, US28, vIL-1013 
10, LUNA and UL138 (blue) were measured in a cohort of 67 HCMV sero-positive and 6 sero-1014 
negative donors.  The production of IL-10 was measured using an IL-10 Fluorospot method; with the 1015 
results converted to spot forming units/million cells (sfu/million) with background counts then 1016 
subtracted.  The response to the HCMV proteins and the positive control by all 73 donors are 1017 
summarized (A) with HCMV sero-positive donors (dark) and HCMV sero-negative donors (light) 1018 
both illustrated.  The positive response threshold cut-off of 100 sfu/million (dashed line) and the 1019 
In revi
ew
HCMV T-cell Responses in Ageing 
 
30 
proportion of donors responding to each HCMV protein is indicated.  The proportion of the 67 sero-1020 
positive donors producing a positive IL-10 response to 1 or more of the 6 Lytic expressed proteins 1021 
(B), 5 latency associated proteins (E) or all 11 HCMV proteins (H) are summarized as pie charts with 1022 
the key to segment color for each graph shown.  Graphs illustrating the breadth of HCMV sero-1023 
positive donors IL-10 response to HCMV proteins correlated with age are illustrated for lytic 1024 
expressed (C), latency associated (F) and all 11 proteins (I); also shown is the summed IL-10 1025 
response to lytic (D), latent (G) and all proteins (J) correlated with age.  Spearman rank correlation 1026 
(Spearman rs (95% Confidence Intervals (CI)) and p values) results are indicated on each graph. 1027 
Figure 6 – CD4+ T cell Donor responses to HCMV LUNA, UL138, pp71, US3 and US28 1028 
proteins were more frequently IL-10 biased. 1029 
The frequency of CD4+ T cells that secrete IFNγ or IL-10 or both in response to stimulation by 1030 
HCMV proteins was measured simultaneously using a dual IFNγ/IL-10 Fluorospot assay.  67 HCMV 1031 
sero-positive donors were analyzed, only donors with above threshold responses for either IFNγ or 1032 
IL-10 (100 sfu/million) to each protein are shown.  The IFNγ (dark grey), IL-10 (white spotted) and 1033 
dual cytokine (red) responses of the donor cohort to US28 (A), LUNA (B), UL138 (C), UL144 (D), 1034 
vIL-10 (E), pp71 (F) US3 (G), pp65 (H), IE2 (I), gB (J) and IE1 (K) are shown as a percentage of the 1035 
total CD4+ T cell (IFNγ + IL-10) response of each donor, the donors are arranged along the x-axis in 1036 
increasing age order. The Lytic expressed proteins axis label is in red (graphs F – K) and the latency 1037 
associated protein responses are labelled in blue (graphs A – E).   1038 
Figure 7 – There was no effect of donor age on the magnitude of latent HCMV load in CD14+ 1039 
Monocytes. 1040 
The DNA of purified CD14+ Monocytes was extracted and HCMV viral load detected using droplet 1041 
digital PCR analysis.  No HCMV was detected in 14 HCMV sero-negative donors tested.  The 1042 
HCMV viral load (copies/10
6
 CD14+ cells) results from 94 HCMV sero-positive donors are shown 1043 
correlated with donor age.   Spearman rank correlation (Spearman rs (95% Confidence Intervals (CI)) 1044 
and p values) analysis is indicated on the graph. 1045 
 Figure 8 – High levels of latent HCMV load in CD14+ monocytes correlates with increased 1046 
frequency and breadth of HCMV specific IFNγ CD8+ T cell responses. 1047 
The HCMV viral load (copies/10
6
 CD14+ cells) from 83 HCMV sero-positive donors was correlated 1048 
with CD8+ HCMV specific T cell responses.  Graphs illustrating the breadth (positive response) of 1049 
individual donors CD8+ IFNγ response to the 6 lytic expressed (red) (A), 5 latency associated (blue) 1050 
(C) and all 11 HCMV proteins (purple) (E) correlated with CD14+ cells HCMV viral load are shown.  1051 
The magnitude of the CD8+ IFNγ response summed for all protein groups is correlated with HCMV 1052 
viral load for lytic (red) (B), latent (blue) (D) and all proteins (purple) (F).  Spearman rank correlation 1053 
(Spearman rs (95% Confidence Intervals (CI)) and p values) results are indicated on each graph. 1054 
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